| Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review |
75 |
| Pathophysiology and treatment of cerebral edema in traumatic brain injury |
38 |
| GABA(A) receptor: Positive and negative allosteric modulators |
32 |
| The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics |
32 |
| The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse |
31 |
| Oxidative stress and DNA damage after cerebral ischemia: Potential therapeutic targets to repair the genome and improve stroke recovery |
30 |
| Injury mechanisms in acute intracerebral hemorrhage |
29 |
| Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models |
28 |
| The entropic brain - revisited |
28 |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act |
27 |
| The pathology and pathophysiology of vascular dementia |
26 |
| Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace |
24 |
| NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update |
23 |
| Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus |
23 |
| The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy |
23 |
| Psychiatry & the psychedelic drugs. Past, present & future |
21 |
| Structural biology of GABA(B) receptor |
20 |
| Spreading depolarization is not an epiphenomenon but the principal mechanism of the cytotoxic edema in various gray matter structures of the brain during stroke |
19 |
| Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets |
19 |
| To eat or to sleep: That is a lateral hypothalamic question |
18 |
| Neurotransmitters in the mediation of cerebral ischemic injury |
17 |
| The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling |
17 |
| Intranasal insulin in Alzheimer's disease: Food for thought |
17 |
| Targeting glycogen synthase kinase-3 for oxidative stress and neuroinflammation: Opportunities, challenges and future directions for cerebral stroke management |
17 |
| New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease |
16 |
| Do ketone bodies mediate the anti-seizure effects of the ketogenic diet? |
16 |
| MRI measurements of Blood-Brain Barrier function in dementia: A review of recent studies |
16 |
| Delta opioid receptor agonists are effective for multiple types of headache disorders |
15 |
| Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease |
15 |
| Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression |
15 |
| Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway |
15 |
| Mechanisms underpinning AMP-activated protein kinase-related effects on behavior and hippocampal neurogenesis in an animal model of depression |
15 |
| Impaired glucocorticoid-mediated HPA axis negative feedback induced by juvenile social isolation in male rats |
15 |
| Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease |
15 |
| Physical exercise prevents cognitive impairment by enhancing hippocampal neuroplasticity and mitochondrial function in doxorubicin-induced chemobrain |
14 |
| Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin |
14 |
| Role of PPAR-beta/delta/miR-17/TXNIP pathway in neuronal apoptosis after neonatal hypoxic-ischemic injury in rats |
14 |
| Environmental enrichment effects on synaptic and cellular physiology of hippocampal neurons |
14 |
| Comparative neuropharmacology of N-(2-methoxybenzyl)-5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats |
14 |
| The role of the orexin system in stress response |
14 |
| Pharmacological profile of mephedrone analogs and related new psychoactive substances |
13 |
| Delta(9)-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions |
13 |
| Glutamine has antidepressive effects through increments of glutamate and glutamine levels and glutamatergic activity in the medial prefrontal cortex |
13 |
| Cell-based and pharmacological neurorestorative therapies for ischemic stroke |
13 |
| Allosteric modulators targeting CNS muscarinic receptors |
13 |
| Behavioral and biochemical sensitivity to low doses of ketamine: Influence of estrous cycle in C57BL/6 mice |
13 |
| Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease |
13 |
| Role of Toll-like receptor mediated signaling in traumatic brain injury |
13 |
| Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy |
13 |
| The role of FOXG1 in the postnatal development and survival of mouse cochlear hair cells |
13 |
